Table 4.
ELISA | IFA1 | IFA2 | IFA1&ELISA | ELISA and IFA2 | IFA1&IFA2 | All three assays | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% Autoantibodies | Enrolment (N=27) | Year 5 (N=70) | Enrolment (n=31) | Year 5 (n=39) | Enrolment (N=14) | Year 5 (N=9) | Enrolment (N=8) | Year 5 (N=20) | Enrolment (N=3) | Year 5 (N=4) | Enrolment (N=8) | Year 5 (N=6) | Enrolment (N=3) | Year 5 (N=3) |
None detected | 44.4 | 45.7 | 38.7 | 53.8 | 42.9 | 44.4 | 62.5 | 65.0 | 66.7 | 50.0 | 50.0 | 50.0 | 66.7 | 66.7 |
dsDNA1 | 7.7 | 5.7 | 6.7 | 5.1 | 0.0 | 11.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.7 | 0.0 | 0.0 |
Ribosomal P | 3.7 | 11.4 | 6.5 | 10.3 | 7.1 | 11.1 | 0.0 | 10.0 | 0.0 | 25.0 | 0.0 | 16.7 | 0.0 | 33.3 |
Ro52/TRIM21 | 11.1 | 21.4 | 22.6 | 20.5 | 21.4 | 11.1 | 0.0 | 20.0 | 0.0 | 25.0 | 0.0 | 0.0 | 0.0 | 0.0 |
SSA/Ro60 | 7.4 | 12.9 | 25.8 | 10.3 | 21.4 | 11.1 | 0.0 | 5.0 | 0.0 | 0.0 | 12.5 | 0.0 | 0.0 | 0.0 |
SSB/La | 7.4 | 7.1 | 0.0 | 5.1 | 0.0 | 0.0 | 0.0 | 5.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Sm | 3.7 | 4.3 | 6.5 | 2.6 | 0.0 | 11.1 | 0.0 | 0.0 | 0.0 | 25.0 | 0.0 | 0.0 | 0.0 | 0.0 |
U1RNP | 3.7 | 7.1 | 0.0 | 5.1 | 0.0 | 0.0 | 0.0 | 5.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Histones | 0.0 | 10.0 | 0.0 | 2.6 | 7.1 | 11.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Patients who were within the normal range for ANA at enrolment are not necessarily the same patients at year 5 and vice versa.
Abbreviations: ANA, anti-nuclear antibodies; β2GP1, β2-glycoprotein-1; dsDNA, double-stranded DNA; ELISA, enzyme-linked immunosorbent assay, IFA; indirect immunofluorescence assay; IgG/M, immunoglobulin G/immunoglobulin M; RNP, ribonucleoprotein; Sm, Smith; TRIM21, TRIpartite Motif protein (TRIM) 21.
dsDNA was measured at enrolment for only 26 patients on ELISA, 13 on IFA2, and 2 on both who tested within the normal range for ANA